Thrilled that my co-authored chapter in this edited volume is finally out! Rozlyn Engel and I do our best to tease out the Biden admin's cautious return to internationalism, and determine where there will be room for progress in international negotiations. @CarnegieEndow
🆕 | Discontent with #globalization has become a powerful dynamic across nations, fueling a backlash against established political systems.
Our report edited by @sinanulgen1 offers proposals for addressing flaws in today's framework of globalization.
👉 https://t.co/86GueWLFzV
In light of recent flooding across WA, @RepRickLarsen@RepKimSchrier & I are calling on Homeland Security Secretary Noem to release $425,000 in already approved flood mitigation funding for Snohomish County immediately so first responders have the resources & information they need to keep our communities safe.
@MatthewKroenig Do you think the strikes were constitutional? Neither Art II nor an existing AUMF would appear to grant authority. Intel Committees weren’t even briefed.
For @ForeignPolicy, I wrote about the fascinating story playing out in southeast Wisconsin, where Trump, Biden, and now Harris have made big promises about bringing back jobs and competing with China—with mixed results.
Here's a gift link to check it out:
https://t.co/fZHqnJ2mEp
@meganmdubois@ForeignPolicy A great read. It moves nimbly between federal enthusiasm for major development works and local skepticism after being burned when projects fail
@petereharrell What kind of prior status would be used for the 1260H list? It seems like most options would require broadening the list criteria in order to rely on unclass. Did the EU lose list specificity when it adopted this approach?
So I might be looking for an intern or temporary research assistant soon. They/you’d work directly with me on some special research projects related to C2, SSA, and directed energy. It’s not crystallized yet, but just throwing it out there. What you write, you publish.
Could the Chinese biotech sector be the next risky frontier between the United States and China? Read this new and timely ASPI and @Cure4C paper by @patbeyrer on U.S.-China biotech competition. https://t.co/9kMfSKJW0K